Five Cases Report of Solid Tumor Synchronously with Hematologic Malignancy

The reported incidence of synchronous multiple primary cancer (SMPC) is rare, and it is even less common to observe synchronous solid tumor with a hematological malignancy. We report five cases of solid tumor presented synchronously with hematological malignancy, all observed within a 2 year period at the oncology department of a university hospital in Shanghai, China. These individual cases included lung adenocarcinoma with chronic myelogenous leukemia, colon cancer with solitary plasmocytoma, gastric adenocarcinoma with diffuse large B cell non-Hodgkin's lymphoma, lung adenocarcinoma with multiple myeloma, and colon cancer with diffuse large B cell non-Hodgkin's lymphoma. It is challenging to therapeutically control the biological behavior of concurrent multiple primary tumors, and there is no standard treatment for such rare conditions. In this paper we discuss these five cases of SMPC and their treatments

An Analysis of Relationship Between RAS Mutations and Prognosis of Primary Tumour Resection for Metastatic Colorectal Cancer Patients

Background/Aims: Non-radical primary tumour resection (PTR) of asymptomatic metastatic colorectal cancer (mCRC) can prolong survival time of some patients. Patients with mutated RAS gene have worse survival outcome. This study aimed to investigate the impact of RAS gene mutations on the prognosis of asymptomatic unresectable mCRC patients who underwent PTR. Methods: A retrospective observational cohort study was deduced among mCRC patients who experienced PTR or had intact primary tumour (IPT). All of them had the primary tumour tissue genotyping tested for RAS (KRAS and NRAS) gene mutations. The tumour-related overall survival (OS) time and progression-free survival (PFS) time was estimated. From January 2011 to June 2014, 421 mCRC patients with asymptomatic, unresectable, metastatic disease were enrolled in this study. Among them, 282 patients underwent PTR and 139 patients had IPT. Results: The mutation rate of RAS was 53.8% (221/411). With a median followed-up time of 46.5 months, the overall survival time of mCRC patients harboring wtRAS or mtRAS was 28.0 versus 22.0 months (p = 0.043) in PTR group and was 21.6 versus 17.8 months (p=0.071) in IPT groups. A Multivariate regression analysis suggested that RAS gene (p=0.039, HR=1.288,95%CI [1.072∼2.911]), metastatic organ number (p=0.033, HR=3.091,95%CI [1.090∼5.755]) and systemic therapy response (p=0.019, HR=0.622,95%CI [0.525∼0.811]) were independent prognostic factors in PTR population. Conclusion: We found that wild-type RAS gene was a favorable factor for the asymptomatic unresectable mCRC patients experiencing PTR

Prognostic implication and immunological value of contactin 1 expression in pan‐cancer

Abstract Objective Contactin 1 (CNTN1) is associated with developing the cancer progression and nervous system. Although increasing evidence suggests a crucial role for CNTN1 in many research areas, it is still no detailed systematic analysis of CNTN1 and the human pan‐cancer spectrum. Here, our purpose is to make a thorough investigation of CNTN1 properties across pan‐cancer types. Methods CNTN1 mRNA expression and genomic alteration were dissected by GTEX, TCGA, and the cBioPortal database. CNTN1 expression in human organic tissues was performed via human multiple organ tissue microarrays. Furthermore, the correlations between CNTN1 and survival periods, clinical characteristics, and immune‐associated cells infiltration were performed through the TCGA database. Additionally, GSEA was carried out to delve into the biological actions of CNTN1 in pan‐cancer. Results We discovered that CNTN1 expression was abnormal in pan‐cancer expression analysis and could predict the survival period of cancers. The primary alteration type of CNTN1 was a genomic mutation. In addition, the aberrant CNTN1 expression was found to be related to MSI, MMR, and TMB in pan‐cancer. CNTN1 was significantly related to the infiltration of immune‐associated cells in certain kinds of cancer through the ESTIMATE algorithm and TIMER database. In particular, the cancer‐associated fibroblasts indicate a negative regulation of the tumor immune microenvironment. Next, we found the most frequent signaling pathway of CNTN1 in human pan‐cancer was neuroactive ligand–receptor interaction from GSEA analysis. Conclusion In conclusion, the investigation highlights the predictive function of CNTN1 in human pan‐cancer and affords novel insights for drawing a landscape of CNTN1 in tumorigenesis and immune regulation

A Joint Automatic Modulation Classification Scheme in Spatial Cognitive Communication

Automatic modulation discrimination (AMC) is one of the critical technologies in spatial cognitive communication systems. Building a high-performance AMC model in intelligent receivers can help to realize adaptive signal synchronization and demodulation. However, tackling the intra-class diversity problem is challenging to AMC based on deep learning (DL), as 16QAM and 64QAM are not easily distinguished by DL networks. In order to overcome the problem, this paper proposes a joint AMC model that combines DL and expert features. In this model, the former builds a neural network that can extract the time series and phase features of in-phase and quadrature component (IQ) samples, which improves the feature extraction capability of the network in similar models; the latter achieves accurate classification of QAM signals by constructing effective feature parameters. Experimental results demonstrate that our proposed joint AMC model performs better than the benchmark networks. The classification accuracy is increased by 11.5% at a 10 dB signal-to-noise ratio (SNR). At the same time, it also improves the discrimination of QAM signals

A New Transient Frequency Acceptability Margin Based on the Frequency Trajectory

When the electric power system is disturbed, the transient frequency deviation may be large and harmful to its stable operation, especially in some small power systems. However, there is a lack of transient frequency acceptability margin (TFAM) which could be directly used by dispatchers. In this paper, a new TFAM is proposed based on the transient frequency acceptability index (TFAI). First, based on the frequency trajectory and the philosophy of “different weights to the different frequency offset levels„, a new TFAI is proposed combined with frequency thresholds and time duration limits. The effectiveness of the TFAI is verified, and the critical acceptable disturbance is determined by using the TFAI. Then, a new TFAM is proposed based on the critical acceptability disturbance. The proposed TFAM can quantitatively describe the distance of the operation point from the critical frequency acceptability point, and distinguish the transient frequency acceptability of different disturbances. Finally, with different simulations, the effectiveness and applicability of the proposed TFAM are verified. The TFAM can be used for disturbances with single-parameter and multiple parameters

Phase I study of adjuvant chemotherapy with nab‐paclitaxel and S‐1 for stage III Lauren's diffuse‐type gastric cancer after D2 resection (NORDICA study)

Abstract Purpose The prognosis of diffuse‐type gastric cancer (DGC) is poorer than that of intestinal type, but S‐1 is a potential treatment option in DGC. This study explored the maximal tolerated dose (MTD) and the recommended dose for phase II study (RP2D) of nab‐paclitaxel combined with S‐1 (AS regimen) as adjuvant chemotherapy in stage III DGC. Methods Patients with stage III DGC were recruited into this phase I dose‐escalation study between July 2019 and June 2020 in Zhongshan Hospital. Nab‐paclitaxel and S‐1 (80–120 mg/day, d1‐14, q3w) were administrated for 6 cycles, and then 8 cycles of S‐1 monotherapy were applied. The patients received nab‐paclitaxel at 180, 220, or 260 mg/m2 according to the 3 + 3 design based on dose‐limiting toxicity (DLT). The primary endpoint was RP2D. Secondary endpoints were the 1‐year disease‐free survival (DFS) rate and adverse events (AEs). Results One case experienced DLT in 180‐mg/m2 dose group, subsequently three additional subjects were enrolled. DLT was not observed in the 220‐ and 260‐mg/m2 dose groups (both n = 3). Therefore, the MTD has not reached, and the RP2D of nab‐paclitaxel would be 260 mg/m2. Five participants showed progressive disease, with three and two participants in the 180‐ and 220‐mg/m2 dose groups, respectively. The 6‐, 12‐, and 18‐month DFS rates were 100%, 63.6%, and 50.9%, respectively. The most frequently observed AEs were neutropenia (83.3%) and leukopenia (66.7%). Conclusion The RP2D of nab‐paclitaxel as adjuvant chemotherapy in DGC was 260 mg/m2. The AS regimen had a tolerable AE profile in stage III DGC

The Efficacy of Bevacizumab Compared with Other Targeted Drugs for Patients with Advanced NSCLC: A Meta-Analysis from 30 Randomized Controlled Clinical Trials

<div><p>Background</p><p>The extent of the benefit of bevacizumab combined with chemotherapy in the treatment of advanced non-small-cell lung cancer (NSCLC) is still unclear. We performed this meta-analysis to compare the efficacy of bevacizumab with other commonly used targeted drugs for different patients with advanced NSCLC.</p><p>Methods</p><p>We searched PubMed, Cochrane Library, EMBASE and abstracts from the proceedings of the American Society of Clinical Oncology (ASCO), and identified 30 randomized controlled clinical trials published within 1999 to 2011 for meta-analysis.</p><p>Results</p><p>The outcomes of treatment efficacy included response rate, PFS and OS. Comparing bevacizumab (15 mg/kg) with chemotherapy to standard chemotherapy alone, for chemotherapy-naïve patients, the pooled OR of response rate was 2.741(95%CI: 2.046, 3.672), the pooled HR for disease progression was 0.645 (95%CI: 0.561, 0.743), and the pooled HR for death was 0.790 (95%CI: 0.674, 0.926), respectively. In addition, the adjusted HR for previously-treated patients was 0.680 (95%CI: 0.492, 0.942) comparing bevacizumab combined with chemotherapy to standard chemotherapy alone.</p><p>Conclusions</p><p>Bevacizumab accompanied by chemotherapy was found to significantly improve patients' response rate, progression free survival (PFS), and overall survival (OS) among chemotherapy-naïve patients compared to other targeted drugs in the treatment of non-small cell lung carcinoma (NSCLC).</p></div